Corporate

You heard it here first.

 
 
 

Our news

Bringing you the latest!

Corporate

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia

Corporate - Investors

31 August 2021

MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report

Corporate

28 July 2021

MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development

Corporate

14 June 2021

Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin

Corporate

19 April 2021

 
 

CONTACT

  • This field is for validation purposes and should be left unchanged.